

healthincode

	BREAST	OVARIAN	UTERINE	COLORECTAL	MELANOMA	PANCREATIC	STOMACH	PROSTATE	MEN	PHEOCHROMO-CYTOMA	PARAGANGLIOMA	RETINOBLASTOMA	KIDNEY
APC				High or moderate risk			High or moderate risk						
ATM	High or moderate risk			Insufficient clinical evidence			Insufficient clinical evidence	High or moderate risk					
BARD1	Low risk			Insufficient clinical evidence									
BMPR1A				High or moderate risk			High or moderate risk						
BRCA1	High or moderate risk	High or moderate risk				High or moderate risk	Insufficient clinical evidence	High or moderate risk					
BRCA2	High or moderate risk	High or moderate risk				High or moderate risk	Insufficient clinical evidence	High or moderate risk					
BRIP1	Insufficient clinical evidence	High or moderate risk						High or moderate risk					
CDH1	High or moderate risk						High or moderate risk						
CDK4					High or moderate risk		High or moderate risk						
CDKN2A					High or moderate risk	High or moderate risk							
CHEK2	High or moderate risk			Low risk				High or moderate risk					
EPCAM		High or moderate risk	High or moderate risk	High or moderate risk			High or moderate risk						
FAM175A								High or moderate risk					
FH										Insufficient clinical evidence			
KIF1B										High or moderate risk			
MAX										High or moderate risk			
MEN1									High or moderate risk				
MET													High or moderate risk
MLH1		High or moderate risk	High or moderate risk	High or moderate risk		High or moderate risk	High or moderate risk						
MLH3				Low risk									
MRE11A	Insufficient clinical evidence							High or moderate risk					
MSH2		High or moderate risk	High or moderate risk	High or moderate risk		High or moderate risk	High or moderate risk	High or moderate risk					
MSH3				Insufficient clinical evidence									
MSH6		High or moderate risk	High or moderate risk	High or moderate risk		Insufficient clinical evidence	High or moderate risk	High or moderate risk					
MUTYH				High or moderate risk									
NBN	High or moderate risk							High or moderate risk					
NF1	High or moderate risk									High or moderate risk			
NTHL1				Insufficient clinical evidence									
PALB2	High or moderate risk							High or moderate risk					
PIK3CA	Insufficient clinical evidence		Insufficient clinical evidence										
PMS2		High or moderate risk		High or moderate risk			High or moderate risk	High or moderate risk					
POLD1				Insufficient clinical evidence									
POLE				Insufficient clinical evidence									
PTEN	High or moderate risk		High or moderate risk	High or moderate risk			Insufficient clinical evidence						
RAD50	Insufficient clinical evidence												
RAD51C		High or moderate risk						High or moderate risk					
RAD51D	Insufficient clinical evidence	High or moderate risk						High or moderate risk					
RB1												High or moderate risk	
RET									High or moderate risk	High or moderate risk	High or moderate risk		
SDHA													
SDHAF2													
SDHB										High or moderate risk	High or moderate risk		
SDHC										High or moderate risk	High or moderate risk		
SDHD										High or moderate risk	High or moderate risk		
SMAD4				High or moderate risk		High or moderate risk	High or moderate risk						
STK11	High or moderate risk	High or moderate risk		High or moderate risk		High or moderate risk	High or moderate risk						
TMEM127										High or moderate risk			
TP53	High or moderate risk			High or moderate risk			Insufficient clinical evidence						
VHL										High or moderate risk			
XRCC2	Insufficient clinical evidence												

- High or moderate risk to develop cancer if a pathogenic alteration is detected in the coding region according to the *NCCN Clinical Practice Guidelines in Oncology* guidelines.
- Low risk to develop cancer if a pathogenic alteration is detected in the coding region according to the *NCCN Clinical Practice Guidelines in Oncology* guidelines.
- Insufficient clinical evidence, but several studies correlate alterations in the coding sequence with the appearance of cancer.